Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Net Cash Flow: 2021-2025

Historic Net Cash Flow for ARS Pharmaceuticals (SPRY) over the last 5 years, with Sep 2025 value amounting to $8.0 million.

  • ARS Pharmaceuticals' Net Cash Flow rose 164.50% to $8.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.9 million, marking a year-over-year increase of 195.33%. This contributed to the annual value of -$20.2 million for FY2024, which is 85.56% up from last year.
  • According to the latest figures from Q3 2025, ARS Pharmaceuticals' Net Cash Flow is $8.0 million, which was down 31.34% from $11.7 million recorded in Q2 2025.
  • In the past 5 years, ARS Pharmaceuticals' Net Cash Flow ranged from a high of $173.2 million in Q4 2022 and a low of -$122.7 million during Q1 2023.
  • Moreover, its 3-year median value for Net Cash Flow was $3.0 million (2024), whereas its average is -$13.7 million.
  • The largest annual percentage gain for ARS Pharmaceuticals' Net Cash Flow in the last 5 years was 508.91% (2023), contrasted with its biggest fall of 1,461.70% (2023).
  • Quarterly analysis of 5 years shows ARS Pharmaceuticals' Net Cash Flow stood at $121.5 million in 2021, then spiked by 42.61% to $173.2 million in 2022, then slumped by 93.97% to $10.4 million in 2023, then grew by 6.91% to $11.2 million in 2024, then skyrocketed by 164.50% to $8.0 million in 2025.
  • Its last three reported values are $8.0 million in Q3 2025, $11.7 million for Q2 2025, and -$11.0 million during Q1 2025.